Ardelyx’s ambition to revolutionise kidney treatment

A therapy to treat hyperphosphatemia is moving closer to the market after years of development by California-based company Ardelyx.

Mallinckrodt’s liver disease drug terlipressin edges FDA adv...

An FDA advisory committee has narrowly voted in favour of approval of Mallinckrodt’s terlipressin for hepatorenal syndrome type 1 (HRS-1), after the agency questioned the findi

3rd Chronic Kidney Disease Drug Development (CKD3) Summit

Advance Therapeutics for Chronic Kidney Diseases

3rd Chronic Kidney Disease Drug Development (CKD3) Summit

Advance Therapeutics for Chronic Kidney Disease

Q&A: Novartis’ Eric Hughes on transplantation

With approximately 3.2 million people worldwide living with end-stage renal disease, there is immense pressure on healthcare systems with long waiting lists for kidney and liver transplants

Smartphone screening project for kidney disease launched in ...